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Summary Analysis of 17 cases of coexistent sarcoidosis and malignant lymphoproliferative disease,
supplemented with 29 similar cases reported in the literature indicates that this association is not fortuitous.
In addition, significantly more malignancies other than lymphoma were found in this group of patients. A
sarcoidosis-lymphoma syndrome appears to exist in which malignant lympho-proliferative disease develops at
least 5.5 times more often than expected in middle-aged patients with chronic active sarcoidosis, possibly as a
consequence of the immunologic abnormalities observed in the latter disease.
Coexistence of sarcoidosis and malignant lympho-
proliferative disease (LD) has been reported
sporadically for the last 50 years, but mostly during
the last two decades (Table I). The assessment of
such reports is difficult. While LD is usually easy to
verify, the presence of true sarcoidosis is often
difficult to prove, even when clinicoradiographic
findings compatible with sarcoidosis are supported
by histologic evidence of non-caseating epitheliod
cell granulomas (EPCG), since infectious agents
and tissue irritants may induce similar histologic
changes (Parkes, 1974; Sharma, 1984). Further, the
occasional occurrence of local sarcoid reactions in
LD, particularly in Hodgkin's disease, complicates
the issue (Kadin et al., 1971; Kim & Dorfman,
1974; Neiman, 1977). Thus, regardless of whether
sarcoidosis is presumed before or after the
verification of LD, it may be argued that the latter
disease is responsible for the occurrence of EPCG,
particularly if both diseases are primarily located to
the skin or the lymph nodes.
Under these circumstances any selection of
reported cases of coexisting sarcoidosis and LD will
be the result of a personal judgement. Table I
presents 29 cases which the author tends to regard
as genuine. However, there are some additional
cases of LD localized to the skin in which it cannot
be determined whether the occurrence of EPCG in
the skin signifies concurrent sarcoidosis or a local
sarcoid reaction (Pautrier, 1938; Kissel et al., 1962;
Ackerman & Flaxman, 1970; Kahn et al., 1974).
Further, there are some reports in which
coexistence of sarcoidosis and LD has been claimed
although it is more likely that mere local sarcoid
reactions have been observed (Hastings &
Thompson, 1949; Wurm et al., 1958; Razis et al.,
1959).
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Analysis of the 29 cases from Table I reveals
three interesting features: (i) With two exceptions
cases of LD have occurred after sarcoidosis with a
median interval of 24 months between the two
diseases. This indicates a possible causal
relationship. (ii) The median age of the patients at
onset of sarcoidosis is 41 years which is 10 years
above the median age of unselected patients with
sarcoidosis (Horwitz et al., 1967). This is interesting
because a late onset of sarcoidosis is quite often
associated with a chronic active type of this disease.
(iii) Hodgkin's disease occurs more frequently than
expected if the association between sarcoidosis and
the various types of LD were merely fortuitous.
Taken together, the three features mentioned
above suggest the existence of a sarcoidosis-
lymphoma syndrome which may evolve through an
immunological mechanism. In order to characterize
this proposed syndrome in more detail a further 17
cases of coexisting sarcoidosis and LD have been
collected and analyzed.
Material and methods
The 17 cases of coexistent sarcoidosis and
malignant LD (Table II) were found by following
anamnestic indications of preceding sarcoidosis,
uncovered at the time of diagnosis of the
malignancy. However, cases 1 and 2 presented with
Hodgkin's disease with lymph-node biopsies also
containing EPCG, and clinical signs of sarcoidosis
did not appear until 5 and 17 years later,
respectively. Cases 1 and 3 were kindly pointed out
to the author by other physicians, cases 4 and 5
surfaced as a result of a nation-wide study of
Hodgkin's disease (Nordentoft et al., 1980), and
cases 9 and 10 were found as a result of an
epidemiological study of 2,544 patients with
respiratory sarcoidosis (Brincker & Wilbek, 1974).
The remaining 11 cases were found by the author
© The Macmillan Press Ltd., 1986468 H. BRINCKER
during routine clinical work over a 17-year period
in a department with a background population of
900,000 people, amounting to 18% of the Danish
population. Cases 1, 2, 3, 13 and 14 have been
published previously (Brincker, 1972) and have
been deleted from Table I.
In all cases the patients' past hospital records
were procured and scrutinized carefully, and all
information on sarcoidosis, malignant LD and
other malignant diseases was recorded. Whenever
indicated previous chest X-rays and histological
slides were reviewed. During this process additional
possible cases were excluded from the study because
they failed to meet the diagnostic criteria for either
sarcoidosis or malignant LD. In all of the
remaining 17 cases the diagnosis of lymphoid
malignancy was histologically confirmed, and in 14
of the cases the diagnosis of sarcoidosis was based
on the demonstration of EPCG in biopsies as well
as the presence of a typical clinical picture. In cases
9, 10 and 15 the diagnosis of sarcoidosis was made
on clinical grounds alone without bioptic
confirmation. However, the clinical pictures were so
unequivocal that in the author's opinion all three
cases should be regarded as bona fide cases of
sarcoidosis (cf. Table III).
Results
Table II gives the overall data on all 17 patients.
There were 9 females and 8 males, and their median
age at the onset of sarcoidosis was 41 years. There
were 8 cases of Hodgkin's disease, 4 of non-
Hodgkin's lymphoma, 3 of chronic lymphocytic
leukaemia, and 2 of paraproteinaemia. The mean
interval from onset of sarcoidosis (in cases 1 and 2
from first biopsy with EPCG) to histologic
verification of malignant LD was 125 months
Table I Coexistence ofsarcoidosis and malignant lymphoma
Age atfirst Sarcoidosis Interval to
Case symptom of confirmed lymphoma Type of
no. Sex sarcoidosis by biopsy (months) tymphoma Reference
1 M 46 yes 4 HD? Pautrier, 1934
2 F 67 yes 2 HD? Lamache et al., 1954
3 M 35 (case 1) yes 48 HD Herbeuval et al., 1960
4 F 28 yes 9 NHL Buckle, 1960
5 F 45 yes 16 NHL Raben et al., 1961
6 M 49 (case 1) yes 72 NHL(MF.?) Atwood et al., 1966
7 M 47 yes 20 NHL Silver et al., 1967
8 F 50 at autopsy 108 NHL Scadding, 1967
9 F 41 yes 48 NHL Scadding, 1967
10 F 38 at autopsy 132 NHL Scadding, 1967
11 F 71 (case 1) yes 8 HD Goldfarb & Cohen, 1970
12 M 36 Kveim+ 72 HD Stoker, 1971
13 F 47 yes 94 MF McFarland et al., 1978
14 F 45 yes 1 HC Myers et al., 1979
15 F 54 yes 2 AILD Turpin et al., 1980
16 F 32 yes 20 NHL Foon et al., 1981
17 M 16 yes 60 HD Ponticelli et al., 1981
18 F 31 yes 48 HD Khayat et al., 1982
19 F 73 yes 14 NHL (§) Cantwell, 1982
20 F 30 (case 1) Kveim+ 24 NHL Casassus et al., 1982
21 M 42 (case 2) yes 144 NHL Casassus et al., 1982
22 M 23 (case 3) yes 84 NHL Casassus et al., 1982
23 F 54 (case 4) yes 2 AILD Casassus et al., 1982
24 M 22 (case 5) yes -108 HD Casassus et al., 1982
25 M 37 yes 24 NHL Rosenfelt et al., 1983
26 F 52 yes -27 NHL Mauduit et al., 1983
27 F 28 yes 18 NHL Brennan et al., 1983
28 M 26 yes 24 HD Regdosz et al., 1984
29 M 31 yes 120 HD Scully et al., 1984
Abbreviations: HD=Hodgkin's disease; NHL=non-Hodgkin lymphoma; MF=mycosis fungoides; HC=hairy cell
leukaemia; AILD=angio-immunoblastic lymphadenopathy with dysproteinemia. §This patient also had two basal cell
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Table H Patient characteristics
Onset Sarcoidosis Interval (mo.)
Case Born of confirmed Type of Lymphoma sarcoidosis Present
no. Sex date sarcoidosis by biopsy Mantoux lymphoma verified to lymphoma status
1 M 2/26 11/68 11/51+11/68 neg HD,MC 11/51 0(-204) aliveNED
2 M 12/15 1/68 6/63+1/68+1/79 ND HD, MC 6/63 0 (-55) alive NED
3 F 1/28 8/60 8/60+7/68 neg HD, LD 7/68 95 alive NED
4 M 4/22 4/61 5/61+6/70 neg HD, MC 12/71+2/72 128 died 6/72
5 F 6/15 10/63 10/63+5/72+6/72 ND HD, MC 5/72 103 died 8/82
6 M 11/52 10/72 1/73+5/73 ND HD, LP 1/73 3 died 7/73
7 F 7/32 10/56 12/56+7/58+5/62 ND HD, MC 2/79+3/80 268 alive NED
8 F 6/16 11/77 10/81 neg HD, MC 10/81 47 died 12/83
9 M 9/11 2/61 no biopsy neg NHL 6/63 28 died 11/64
10 F 2/10 8/64 no biopsy neg NHL 10/68 50 died 8/69
11 F 3/24 5/75 6/75 pos NHL 2/84 105 alive NED
12 M 6/46 6/72 5/84 neg NHL 5/84 143 alive NED
13 F 8/09 7/50 autopsy 12/83 neg CLL 7/64 168 died 12/83
14 M 4/05 10/41 3/42 neg CLL 1/69 327 died 7/79
15 F 9/14 3/74 no biopsy neg CLL 3/75 12 alive ED
16 M 9/12 11/53 3/54 pos MM, IgG-K 9/76 274 died 6/77
17 F 8/29 1/53 1/53 neg MCG, K 6/84 377 alive ED
All dates given as month/year. ND=not done; NED=no evidence of malignant lymphoproliferative disease;
HD=Hodgkin's disease; MC=mixed cellularity; LD=lymphocytic depletion; LP=lymphocytic predominance;
NHL=non-Hodgkin's lymphoma; CLL=chronic lymphocytic leukaemia; MM, IgG-K=multiple myeloma of IgG
kappa type; MCG, K=monoclonal gammopathy of kappa type; ED=evidence ofmalignant lymphoproliferative disease.
(median 95 months). The mean interval from
sarcoidosis to malignant LD was 81 months for
Hodgkin's disease, 89 months for non-Hodgkin's
lymphoma, 169 months for chronic lymphocytic
leukaemia and 326 months for paraproteinaemia.
The longest interval was 31 5/12 years (case 17).
Five of the 9 deceased patients had autopsies (cases
4, 5, 6 12 and 14). Only in case 6 with the shortest
interval from onset of sarcoidosis to autopsy were
EPCG found at autopsy. In the remaining 4 cases
fibrotic changes were found in lymph-nodes or
lungs, consistent with old, healed sarcoidosis.
Table III summarizes the observed clinical
manifestations of sarcoidosis. Fifteen of the 17
cases had involvement of lung parenchyma or hilar
lymph-nodes, and in 9 cases the symptoms were
sufficiently severe to justify systemic corticosteroid
therapy. Some cases healed spontaneously or
following therapy (cases 1, 9, 14, 16 and 17), but it
is remarkable that the remaining cases all had later
exacerbations or problems due to progressive
pulmonary fibrosis. In many of the patients
sarcoidosis was diagnosed long ago when diagnostic
work-up was more cursory than today.
Accordingly, there were too few serum protein
determinations (n=6) to allow a meaningful
analysis. However, there were enough cell counts to
show that the median number of lymphocytes per
M1 of peripheral blood was only 1,056 (range, 303-
1,750) at the diagnosis of sarcoidosis, and only 864
later at the diagnosis of malignant LD. These
figures are well below the lowest normal range.
Nine cases of associated neoplastic disease were
found, 7 of which were malignant tumours (Table
IV). Remarkably, these 9 cases occurred in only 5
patients. The case of acute myelocytic leukaemia
may have been iatrogenic, following 10 years of
chlorambucil treatment. Further, this patient had
had several courses of 165KVX-ray therapy in
1942-43 because of furunculosis. Five of the 17
malignant tumours occurred after the diagnosis of
sarcoidosis and 2 before. The total number of cases
of malignant tumours expected to occur in all 17
patients was calculated both for the period of birth
to last date of observation and for the period of
onset of sarcoidosis to last day of observation,
using published Danish incidence figures (Danish
Cancer Registry, 1982). Table V shows that
significantly more malignant tumours occurred than
expected (P= <0.05), regardless of the method of
calculation.
Discussion
The three features of the proposed sarcoidosis-
lymphoma syndrome apparent from the literature
review (Table I) were all confirmed by the present470 H. BRINCKER
Table III Clinical manifestations of sarcoidosis
Case Number
Age at onset
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
42 52 32 39 48 19 24 61 49 54 51 26 40 36 59 41 23
Fever
Loss ofweight
Cough
Dyspnoea
Hilar enlargement
Lung infiltrates
Enlarged lymph nodes
Hepatosplenomegaly
Arthritis
Erythema nodosum
Cutaneous infiltrates
Hypercalcaemia
Bone lesions
Eye lesions
Other
Corticosteroids given
(before diagnosis of
malignant lymphoma)
+ + +
+ +
+ + +
+ + +
+ + +
+ + +
+ + +
+
+ +
+
+
+
+ + +
+ + +
+
+ + + +
+ + +
+ + + + +
+ +
+ + +
+
+
+ + + + + +
+ +
+ +
+ +
Median number of lymphocytes pl1- at onset of sarcoidosis: 1,056 (9 samples). Median number of lymphocytes
p1l1 at diagnosis oflymphoma: 864 (12 samples).
Table IV Associated neoplastic diseases
1st symptom
Case Born of Lymphoma Additional neoplastic disease
no. Sex date sarcoidosis verified Type
2 M 12/15 6/63 6/63 Squamous carcinoma of lip 12/58
Leucoplakia of false vocal cord 5/60
Basal cell c:t-cinoma ofcheek 1/79
5 F 6/12 10/63 5/72 Carcinoma ofuterine cervix 3/80
Carcinoma of vulva 4/80
7 F 7/32 10/56 2/79 Carcinoma of breast 4/81
13 F 8/09 7/56 7/64 Carcinoma of uterine cervix 5/35
Mixed pseudomucinous and
serous ovarian cyst 7/53
14 M 4/05 10/41 1/69 Acute myelocytic leukaemia 6/79
Table V Associated neoplasia
Males Females Total
Development ofmalignant
tumors ofall types Expected Observed Expected Observed Expected Observed
From birth to last date
of observation 1.30 3a 1.35 4b 2.65 7(P= <0.05)
From onset of sarcoidosis
to last date of observation 0.77 2 0.82 3b 1.60 5(P= <0.05)
aPlus one case of leucoplakia of false vocal cords; bPlus one case of ovarian cyst (mixed serous and pseudo-
mucinous).
+ + +
+ +
+ + + + +
+ +
+
+ + + +
+
+
+
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study, viz. that LD always occurs after sarcoidosis,
that the median age at onset of sarcoidosis is 10
years above that of unselected sarcoidosis patients,
and that Hodgkin's disease occurs more frequently
than expected.
The median interval from the onset of sarcoidosis
was almost 4 times longer than in the previously
reported cases, 95 versus 24 months. Whether this
interval is shorter in Hodgkin's disease and in non-
Hodgkin's lymphoma than in chronic lymphocytic
leukaemia and paraproteinaemia is uncertain due to
the small number of cases. The relatively long
interval from sarcoidosis to LD found in the
present study may simply reflect the author's
interest in following up anamnestic leads of
preceding sarcoidosis in lymphoma patients. In
none of the 17 cases did LD precede sarcoidosis.
Cases 1 and 2 of Table II are really no exception to
this rule since EPCG were demonstrated concomi-
tantly with LD although the clinical manifestations
of sarcoidosis did not appear until later.
The impression that the sarcoidosis-lymphoma
syndrome is associated with a chronic active type of
sarcoidosis appears to have been confirmed by the
present study. Thus, the median age of the patients
was rather high (41 years as in previously reported
cases), they had long-term lymphopenia, 85% were
anergic, 53% had received corticosteroid treatment,
and 71% had signs of persistent disease activity.
These factors are usually associated with significant
immunologic abnormalities typical of sarcoidosis,
viz. an increased number of T helper cells in
granulomatous tissues, a decreased number of
circulating T helper cells, and hyperactivity of the B
cell system (Daniele et al., 1980).
There were twice as many cases of Hodgkin's
disease as of non-Hodgkin's lymphoma in the
present study whereas the latter type of lymphoma
dominated among the previously reported cases (15
versus 10, Table I). The reason for this discrepancy
is not clear. In any case, Hodgkin's disease occurs
more frequently than expected. This agrees with a
previous epidemiological study of cancer incidence
in 2,544 patients with respiratory sarcoidosis. Here
6 cases of malignant lymphoma occurred against
0.52 cases expected. Four cases were Hodgkin's
disease and 2 non-Hodgkin's lymphoma (Brincker
& Wilbek, 1974). It is puzzling why both true
sarcoidosis and local sarcoid reactions should be
associated particularly with one type of LD (Kadin
et al., 1971; Kim & Dorfman, 1974; Neiman, 1977).
However, all combinations of sarcoidosis and LD
appear to occur (Tables I and II) with the possible
exception of acute lymphocytic leukaemia.
The finding of a significantly increased incidence
of various malignant tumours is at variance both
with previously reported cases and with the
aforementioned epidemiological study in which lung
cancer was the only malignancy apart from LD
occurring more frequently than expected with 9
cases observed versus 2.8 expected (Brincker &
Wilbek, 1974). It is interesting, however, that
whereas the median age at onset of sarcoidosis
among all the 2,544 cases in the previous study was
30 years, it was 56 years in those 24 patients who
subsequently developed a malignant tumour other
than LD (unpublished observations). Thus, here as
in LD there is a suggestion that it is the chronic
active type of sarcoidosis developing in middle-aged
patients which is associated with subsequent
development ofmalignant disease.
The chronology of sarcoidosis, LD and other
malignant tumours viewed together with the
evidence of immunological abnormalities in the
patients studied (anergy, lymphopenia, persistent
disease activity) makes it natural to look for
immunological mechanisms behind the sarcoidosis-
lymphoma syndrome. It has long been known that
patients with congenital or acquired
immunodeficiency syndromes and with certain
immunoinflammatory diseases often develop
lymphomas, and it has been proposed that the
increased mitotic activity of lymphocytes increases
their risk of mutation and subsequent malignant
transformation, because a failure exists of feedback
mechanisms to regulate lymphocyte proliferation
(Louie & Schwartz, 1978). Since the mitotic activity
of lymphocytes appears to be increased also- in
sarcoidosis due to the immune inflammatory
response in the involved tissues (Daniele et al.,
1980), sarcoidosis probably belongs to the group of
lymphoma-associated diseases mentioned. It is more
difficult to explain the increased incidence of
malignant tumours other than LD in sarcoidosis.
However, the depletion of circulating T helper cells
might lead to decreased tumour rejection (Vose &
Moore, 1985) or perhaps to decreased resistance
against oncogenic viruses. In this context it may be
significant that 6 of the 9 neoplasms found in the
patients studied (Table IV) and the excess cases of
lung cancer found in the previous study (Brincker
& Wilbek, 1974) originated from surface epithelium
of the respiratory tract, the skin, and the female
genital tract - all sites that are frequently exposed
to various carcinogenic stimuli.
Although the present study was not designed to
answer the question whether more cases of LD are
observed in sarcoidosis than expected, it allows
some estimates to be made. The prevalence of
sarcoidosis in Scandinavia has been found to be in
the range of 7.5-64/100,000, but it may be higher
(Sharma, 1984; Teirstein & Lesser, 1983). If we use
the upper figure of 64/100,000, the total number of
cases of sarcoidosis in Denmark (with a population472 H. BRINCKER
of 5 million people) would be 3,200. The yearly
incidence of LD is about 1 in 5,000 - in other
words, 0.64 cases of LD should be expected to
occur yearly in patients with sarcoidosis as a result
of chance alone. Since 11 of the 17 patients in the
present study were collected over a 17-year period
from an underlying population representing 18% of
the Danish population, this corresponds to about
60 patients for the entire country over a 17-year
period, or 3.5 patients yearly. Thus, the observed
number of cases appears to be about 5.5 times the
expected number, which supports the hypothesis of
sarcoidosis as a predisposing factor for LD. The
5.5/1 ratio is lower than the 11.5/1 ratio found in
the previous epidemiological study (Brincker &
Wilbek, 1974), and the correct figure may lie in
between since both methods of calculation are
hampered by uncertainties.
In conclusion, a sarcoidosis-lymphoma syndrome
appears to exist in which LD and other
malignancies develop more often than expected in
middle-aged patients with chronic active
sarcoidosis, perhaps as a consequence of the
immunologic abnormalities observed in the latter
disease.
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